The EINSTEIN-CHOICE findings presented at the American College of Cardiology 66th Session demonstrated some promising outcomes, showing that rivaroxaban is a viable option for long-term prevention of venous thromboembolism in some patients, said Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC, professor of medicine at the Hofstra Northwell School of Medicine.
The EINSTEIN-CHOICE findings presented at the American College of Cardiology 66th Session demonstrated some promising outcomes, showing that rivaroxaban is a viable option for long-term prevention of venous thromboembolism (VTE) in some patients, said Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC, professor of medicine at the Hofstra Northwell School of Medicine.
Transcript (slightly modified)
What will the EINSTEIN-CHOICE findings mean for clinical practice?
I think these are significant, because what we know now is that there is a significant proportion of patients, particularly with unprovoked VTE, that go on to develop recurrent events within 2, 3, 5 years, et cetera. So having a strategy that incurs a greater efficacy than what was once thought in terms of either placebo, which the EINSTEIN extension trial showed us a while back, but now importantly with aspirin, as that has been heralded as an option.
Again, an important about 60 to 70% risk reduction compared to active therapy aspirin with no added risk of bleeding tells us that now patients with likely unprovoked disease, specifically, could probably benefit from long-term secondary thromboprophylaxis.
Now, there’s some caveats. There was some equipoise as to patients who the investigator thought already should be on extended secondary thromboprophylaxis were likely not good candidates for this trial. Also, patients with provoked disease, unless there are what we call constant risk factors, such as malignancy, et cetera, usually those patients will go on an anticoagulant strategy for 3 to 6 months.
But nevertheless, I think in most of the categories of unprovoked VTE, and some categories of provoked VTE, especially with what we call constant VTE risk factors, they would benefit from a long-term secondary prophylactic strategy.
So indeed, what we’re seeing with unprovoked VTE is very similar to the realm of cardiovascular disease. Once you have an event, you likely would benefit from long-term secondary thromboprophylaxis, provided that the bleeding risk is either low to moderate.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More